P335: GCP Compliance Challenges Stem From Training Gaps in Clinical Research Practices
Poster Presenter
Kaili Kulbacki
Clinical Research Professional
Solaire Solutions LLC United States
Objectives
Inadequate investigator training gaps appear consistently in FDA inspections and lead to challenges in implementing and executing clinical research studies. Many clinical investigators receive GCP certification but lack specific training in study protocols, clinical safety reporting requirements and documentation practices.
Method
This investigation reviewed FDA Inspection Classification Database records and Warning Letters from 2020 to 2025 to identify trends in investigator noncompliance. Among 644 investigators[KK1.1], 1,585 individual 21 CFR violations were documented, most frequently 21 CFR 312.60 and 312.62. Initial inspections accounted for 67% of violations, the majority classified as Voluntary Action Indicated (VAI). Repeat infractions showed higher rates of Official Action Indicated (OAI). Oncology investigators exhibited the highest volume of violations[KK2.1]. These findings confirm the gaps in GCP competency and highlight the need for strengthened investigator training, mentorship, and ongoing regulatory education.
Results
Clinical investigators play a central role in ensuring the safety of trial participants and the integrity of clinical research data. To support these responsibilities, the FDA and international regulatory bodies have established comprehensive ethical and operational standards governing clinical trial conduct. In the United States, these requirements are codified in Title 21 of the Code of Federal Regulations (CFR)—including 21 CFR Parts 50, 56, 312, and 812—which outline essential obligations related to informed consent, institutional review board (IRB) oversight, investigational product management, protocol adherence, and accurate recordkeeping7. These regulations are complemented by the International Council for Harmonization (ICH) E6(R2) Good Clinical Practice (GCP) Guideline, which serves as a global framework for ethical and scientific trial execution8.
These regulatory standards are critical because investigators function as the primary supervisors of participant protection and data reliability8. When investigators fail to meet their obligations, whether through inadequate oversight, insufficient documentation, or poor protocol compliance, the consequences can be significant. Noncompliance may compromise subject safety, undermine data validity, delay product development, or trigger regulatory intervention such as FDA Form 483 observations, Warning Letters, or even disqualification proceedings8. Moreover, lapses in fundamental GCP practices can impair the credibility of research findings and erode public trust in the clinical research system.
Conclusion
The overarching goal of this research was to determine whether investigator inexperience is associated with a greater likelihood or particular pattern of GCP violations. Findings from this study aim to support evidence-based improvements in investigator training, regulatory oversight, and GCP education programs to enhance the overall quality, compliance, and integrity of clinical research.
The primary hypothesis is that first-time offenses will represent the majority of documented infractions. This projection reflects the likelihood that many investigators included in the dataset are early-career or research-naïve clinicians who enter clinical trials with limited operational training and incomplete familiarity with Good Clinical Practice (GCP) standards.
